Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: BNC003
MIFTS: 56

Bone Cancer

Categories: Bone diseases, Cancer diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Bone Cancer

About this section

MalaCards integrated aliases for Bone Cancer:

Name: Bone Cancer 12 43 15
Malignant Bone Neoplasm 12 17 72
Bone Carcinoma 12 15 72
Bone Neoplasms 75 44 72
Bone Neoplasm 12 17
Malignant Neoplasm of Bone 12
Malignant Osseous Tumor 12
Malignant Bone Tumour 12
Osteosarcoma of Bone 72
Osteogenic Neoplasm 72
Ca - Bone Cancer 12
Neoplasm of Bone 12
Osseous Tumor 12
Bone Tumour 12

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Bone diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:184 DOID:2762
MeSH 44 D001859
NCIt 50 C36082 C9343
UMLS 72 C0005967 C0279530 C0585442 more
Sources

Summaries for Bone Cancer

About this section
MedlinePlus : 43 Cancer that starts in a bone is uncommon. Cancer that has spread to the bone from another part of the body is more common. There are three types of bone cancer: Osteosarcoma - occurs most often between ages 10 and 19. It is more common in the knee and upper arm. Chondrosarcoma - starts in cartilage, usually after age 40 Ewing's sarcoma - occurs most often in children and teens under 19. It is more common in boys than girls. The most common symptom of bone cancer is pain. Other symptoms vary, depending on the location and size of the cancer. Surgery is often the main treatment for bone cancer. Other treatments may include amputation, chemotherapy, and radiation therapy. Because bone cancer can come back after treatment, regular follow-up visits are important. NIH: National Cancer Institute

MalaCards based summary : Bone Cancer, also known as malignant bone neoplasm, is related to ewing sarcoma and pain agnosia, and has symptoms including back pain, sciatica and muscle cramp. An important gene associated with Bone Cancer is TNFSF11 (TNF Superfamily Member 11), and among its related pathways/superpathways are TNFR1 Pathway and Pathways in cancer. The drugs Dopamine and Methamphetamine have been mentioned in the context of this disorder. Affiliated tissues include bone, prostate and breast, and related phenotypes are behavior/neurological and growth/size/body region

Disease Ontology : 12 A connective tissue cancer that is located in bone and is characterized by uncontrolled cellular proliferation that destroys normal bone tissue.

Wikipedia : 75 A bone tumor is a neoplastic growth of tissue in bone. Abnormal growths found in the bone can be either... more...

Sources

Related Diseases for Bone Cancer

About this section

Diseases in the Bone Cancer family:

Primary Bone Cancer

Diseases related to Bone Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 321)
# Related Disease Score Top Affiliating Genes
1 ewing sarcoma 31.9 MMP9 IL6 EWSR1 CYCS BMI1
2 pain agnosia 31.1 TRPV1 PDYN CNR1
3 bone disease 30.9 TNFSF11 TNFRSF11A IL6 COL1A1
4 osteomyelitis 30.9 TNFSF11 IL6 BMP2
5 giant cell tumor 30.8 TNFSF11 TNFRSF11A MMP9
6 villonodular synovitis 30.5 TNFSF11 MMP9
7 bone resorption disease 30.3 TRPV1 TNFSF11 TNFRSF11A IL6 ESR1 COL1A1
8 bone inflammation disease 30.3 TRPV1 TNFSF11 IL6 CCL2
9 connective tissue cancer 30.1 TRPV1 TNFSF11 EWSR1 COL1A1
10 breast adenocarcinoma 30.0 TNFSF11 MMP9 ESR1 CYCS
11 osteoporosis 29.7 TNFSF11 TNFRSF11A IL6 ESR1 COL1A1 BMP2
12 chest wall bone cancer 12.3
13 primary bone cancer 12.3
14 osteogenic sarcoma 11.6
15 bone marrow cancer 11.5
16 bone squamous cell carcinoma 11.3
17 aneurysmal bone cysts 11.3
18 chondrosarcoma 11.3
19 li-fraumeni syndrome 11.2
20 retinoblastoma 11.2
21 bone giant cell tumor 11.2
22 paget's disease of bone 11.2
23 maxillary cancer 11.1
24 multiple enchondromatosis, maffucci type 11.1
25 enchondromatosis, multiple, ollier type 10.9
26 rapadilino syndrome 10.9
27 rothmund-thomson syndrome 10.9
28 long bones of lower limb cancer 10.9
29 diamond-blackfan anemia 10.9
30 jaw cancer 10.9
31 orbital cancer 10.9
32 sternum cancer 10.9
33 femoral cancer 10.9
34 bone lymphoma 10.9
35 polyarticular onset juvenile idiopathic arthritis 10.8 TNFSF11 TNFRSF11A
36 hemophilic arthropathy 10.8 TNFSF11 TNFRSF11A
37 tooth ankylosis 10.8 TNFSF11 BMP2
38 cyclic vomiting syndrome 10.8 IL6 CNR1
39 agnosia 10.8 TRPV1 PDYN CNR1
40 breast leiomyosarcoma 10.7 TNFSF11 TNFRSF11A
41 osteopetrosis, autosomal recessive 7 10.7 TNFSF11 TNFRSF11A
42 specific developmental disorder 10.7 TRPV1 PDYN CNR1
43 tooth resorption 10.7 TNFSF11 TNFRSF11A BMP2
44 ischemic bone disease 10.7 TNFSF11 TNFRSF11A BMP2
45 periapical periodontitis 10.7 TNFSF11 TNFRSF11A IL6
46 root resorption 10.7 TNFSF11 TNFRSF11A P2RX7
47 periodontitis, chronic 10.7 TNFSF11 IL6
48 paget disease of bone 5, juvenile-onset 10.7 TNFSF11 TNFRSF11A
49 drug dependence 10.7 PENK PDYN CNR1
50 hallucinogen dependence 10.6 PENK CNR1

Graphical network of the top 20 diseases related to Bone Cancer:



Diseases related to Bone Cancer
Sources

Symptoms & Phenotypes for Bone Cancer

About this section

UMLS symptoms related to Bone Cancer:


back pain, sciatica, muscle cramp

MGI Mouse Phenotypes related to Bone Cancer:

46 (show all 16)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.33 CNR1 COL1A1 CYCS ESR1 IL6 MMP9
2 growth/size/body region MP:0005378 10.31 BMP2 CNR1 COL1A1 CYCS ESR1 IL6
3 cellular MP:0005384 10.26 BMP2 CNR1 COL1A1 CYCS ESR1 IL6
4 immune system MP:0005387 10.25 BMP2 CCL2 COL1A1 CYCS ESR1 IL6
5 homeostasis/metabolism MP:0005376 10.23 BMP2 CNR1 COL1A1 ESR1 IL6 MMP9
6 cardiovascular system MP:0005385 10.19 BMP2 COL1A1 CYCS ESR1 IL6 MMP9
7 hematopoietic system MP:0005397 10.18 BMP2 COL1A1 CYCS ESR1 IL6 MMP9
8 integument MP:0010771 10.14 CNR1 COL1A1 ESR1 IL6 MMP9 P2RX7
9 digestive/alimentary MP:0005381 10.11 BMP2 CNR1 COL1A1 ESR1 IL6 MMP9
10 adipose tissue MP:0005375 10.03 CNR1 COL1A1 ESR1 IL6 PDYN TRPV1
11 limbs/digits/tail MP:0005371 9.91 BMP2 COL1A1 ESR1 MMP9 P2RX7 TNFRSF11A
12 neoplasm MP:0002006 9.87 COL1A1 ESR1 IL6 MMP9 TNFRSF11A TNFSF11
13 no phenotypic analysis MP:0003012 9.86 CNR1 COL1A1 ESR1 PDYN PENK TNFRSF11A
14 reproductive system MP:0005389 9.81 BMP2 CNR1 COL1A1 ESR1 IL6 MMP9
15 respiratory system MP:0005388 9.5 COL1A1 ESR1 IL6 MMP9 MTAP TNFRSF11A
16 skeleton MP:0005390 9.36 BMP2 CNR1 COL1A1 CYCS ESR1 IL6
Sources

Drugs & Therapeutics for Bone Cancer

About this section

Drugs for Bone Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 266)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Dopamine Approved Phase 4 51-61-6, 62-31-7 681
2
Methamphetamine Approved, Illicit Phase 4 537-46-2 10836
3
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
4
Calcium Approved, Nutraceutical Phase 4 7440-70-2 271
5 Sympathomimetics Phase 4
6 Adrenergic Agents Phase 4
7 Dopamine Agents Phase 4
8 Neurotransmitter Uptake Inhibitors Phase 4
9 Dopamine Uptake Inhibitors Phase 4
10 Diphosphonates Phase 4
11 Immunoglobulin G Phase 4
12 Analgesics Phase 4
13 Peripheral Nervous System Agents Phase 4
14 Psychotropic Drugs Phase 4
15 Tranquilizing Agents Phase 4
16 Hormones Phase 4
17 Anti-Anxiety Agents Phase 4
18 Anticonvulsants Phase 4
19 Calcium, Dietary Phase 4
20 calcium channel blockers Phase 4
21 sodium fluoride Approved Phase 3 7681-49-4
22
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
23
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3 1177-87-3
24
Temozolomide Approved, Investigational Phase 3 85622-93-1 5394
25
Irinotecan Approved, Investigational Phase 3 100286-90-6, 97682-44-5 60838
26
Cefazolin Approved Phase 3 25953-19-9 656510 33255
27
Ethanol Approved Phase 3 64-17-5 702
28
Phenol Approved, Experimental Phase 3 108-95-2 996
29
Etidronic acid Approved Phase 3 2809-21-4, 7414-83-7 3305
30
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
31 Cranberry Approved, Investigational Phase 3
32 Grape Approved Phase 3
33
Modafinil Approved, Investigational Phase 3 68693-11-8 4236
34
nivolumab Approved Phase 3 946414-94-4
35
Ipilimumab Approved Phase 3 477202-00-9
36
Captopril Approved Phase 3 62571-86-2 44093
37
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
38
Vincristine Approved, Investigational Phase 3 57-22-7, 2068-78-2 5978
39
Cyclophosphamide Approved, Investigational Phase 3 50-18-0, 6055-19-2 2907
40
Ifosfamide Approved Phase 3 3778-73-2 3690
41
Etoposide Approved Phase 3 33419-42-0 36462
42
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
43
Daunorubicin Approved Phase 3 20830-81-3 30323
44
Topotecan Approved, Investigational Phase 3 123948-87-8, 119413-54-6 60700
45
Tranexamic Acid Approved Phase 3 1197-18-8 5526
46
Zoledronic Acid Approved Phase 3 118072-93-8 68740
47
Molybdenum Approved Phase 3 7439-98-7 185498
48
Etanercept Approved, Investigational Phase 2, Phase 3 185243-69-0
49
Camptothecin Experimental Phase 3 7689-03-4
50
Emodepside Investigational, Vet_approved Phase 3 155030-63-0

Interventional clinical trials:

(show top 50) (show all 253)
# Name Status NCT ID Phase Drugs
1 An Open Label Study of the Efficacy, Safety, and Pharmacoeconomics of Oral Ibandronate (Bondronat 50 mg) in Treatment of Metastatic Bone Disease Completed NCT02564107 Phase 4 Ibandronate
2 A Phase IV Study of Zoledronic Acid Therapy in Patients With Bone Metastases From Breast Cancer or Hormone Resistant Prostate Cancer, or Bone Involvement From Multiple Myeloma, Assessing Long-term Efficacy and Safety Completed NCT00434447 Phase 4 Zoledronic acid
3 Open-Label Study to Establish the Short Term Efficacy of Intravenous Loading-Doses of Bondronat 6 mg in Patients With Breast Cancer and Skeletal Metastases Experiencing Moderate to Severe Pain, Within 7 Days After Initiation of Treatment Completed NCT02553707 Phase 4 Ibandronate
4 Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis Completed NCT00241111 Phase 4 zoledronic acid
5 Effect of Zoledronic Acid in Patients With Prostate Cancer and Bone Metastasis Completed NCT00237159 Phase 4 Zoledronic acid
6 Efficacy and Safety Study of ZOMETA® in Treatment of High-level NTX Non Small Cell Lung Cancer With Bone Metastasis Completed NCT00762346 Phase 4 zometa
7 An International Multicentric, Multidisciplinary Prospective and Randomized Study to Compare Minimally Invasive Reduction and Fixation Using the KyphX System and Radiopaque PMMA Cement to Medical Therapy Alone for the Treatment of Painful, Acute Osteopenic Vertebral Body Compression Fractures Completed NCT00211211 Phase 4
8 A Multi-center Observational Clinical Study of Screening of Non-small-cell Lung Cancer With Bone Metastasis and Efficacy and Safety of Those Receiving Bisphosphonates Completed NCT00765687 Phase 4 bisphosphates
9 A Prospective, Single-arm Multicenter Study to Evaluate Effect of Intravenous Zoledronic Acid on Bone Metabolism Given Over 4 Months in Patients With Prostate Cancer or Breast Cancer and Bone Metastasis Completed NCT00334139 Phase 4 Zoledronic Acid
10 A Study to Determine Correlation of MR Thermal Imaging to Actual Size of Ablation During Laser Therapy of Metastases to Bone Completed NCT00688038 Phase 4
11 A Multicenter, Open-label, Randomized Trial to Evaluate the Anti-cancer Effects of Zoledronic Acid and Circulating Tumor Cell Measurements in Patients With HER2-negative Metastatic Breast Cancer Without Bone Metastasis Completed NCT01129336 Phase 4 Zoledronic acid;Standard Therapy
12 Bioactive Glass Granules as Bone Graft Substitute in Filling Material of Bone Defects Completed NCT01304121 Phase 4
13 A Phase 4 Long-term Follow-up Study to Define the Safety Profile of Radium-223 Dichloride Recruiting NCT02312960 Phase 4
14 Long-term Safety Follow-up of Subjects With Giant Cell Tumor of Bone Treated With Denosumab in Study 20062004 Active, not recruiting NCT03301857 Phase 4 Denosumab (Cohort A)
15 Zoledronic Acid Combined Radiotherapy for Bone Metastasis of Non-small Cell Lung Cancer: A Non-inferiority, Randomized, Open, Parallel and Controlled Prospective Clinical Study Not yet recruiting NCT02480634 Phase 4 Zoledronic acid
16 A Randomized Placebo-Controlled Trial Of The Efficacy And Tolerability Of Flexibly Dosed Pregabalin In The Treatment Of Cancer-Induced Bone Pain Terminated NCT00381095 Phase 4 Pregabalin;Placebo
17 Biological Image Guided Antalgic Stereotactic Body Radiotherapy of Bone Metastases: a Randomized Phase II/III Trial Unknown status NCT01429493 Phase 2, Phase 3
18 18F-Fluoride PET/CT Versus 99mTc-MDP Scanning for Detecting Bone Metastases: A Randomized, Multi-Center Trial to Compare Two Bone Imaging Techniques Unknown status NCT00882609 Phase 3
19 Clinical, Pathologic Characteristics and Its Mechansim of Denosumab Treated Giant Cell Tumor of Bone Unknown status NCT03259152 Phase 3 Denosumab
20 Laser Therapy Prevents Mucositis Oral in Patients Undergoing to Chemotherapy for Bone Marrow Transplantation? A Randomized Clinical Trial. Unknown status NCT02020928 Phase 3
21 Randomized, Open Label Study to Evaluate Renal Safety of Intravenous Bondronat 6 mg Infusions Over 15 Minutes Versus 60 Minutes in Patients With Metastatic Bone Disease Due to Breast Cancer Completed NCT02716792 Phase 3 Ibandronate
22 A Randomized, Double-blind, Multi-centre Study to Evaluate the Fficacy and Safety of Zometa as a Treatment in Patients With Bone Metastases of Any Solid Tumors or Multiple Myeloma Completed NCT00219258 Phase 3 Zoledronic acid
23 Randomized, Open Label Study to Assess the Efficacy and Safety of the Intravenous and Oral Ibandronic Acid for Improving the Performance Status of Patients With Malignant Bone Disease Secondary to Solid Tumors and Hematological Malignancies Completed NCT02561039 Phase 3 Ibandronate
24 Open-Label Access Protocol of Denosumab for Subjects With Advanced Cancer Completed NCT01419717 Phase 3 denosumab
25 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Men With Hormone-Refractory Prostate Cancer Completed NCT00321620 Phase 3 zoledronic acid
26 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa®) in the Treatment of Bone Metastases in Subjects With Advanced Breast Cancer Completed NCT00321464 Phase 3 Zoledronic Acid
27 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid (Zometa) in the Treatment of Bone Metastases in Subjects With Advanced Cancer (Excluding Breast and Prostate Cancer) or Multiple Myeloma. Completed NCT00330759 Phase 3 Zoledronic Acid
28 An Open Label, Single Arm, Extension Study to Evaluate the Long Term Safety of Denosumab in the Treatment of Bone Metastases in Subjects With Advanced Cancer or Multiple Myeloma Completed NCT00950911 Phase 3 amg 162
29 Randomized Trial of Vertebroplasty and Radiotherapy Versus Radiotherapy Alone for Osseous Spine Metastases Completed NCT00267033 Phase 3
30 A Randomized Phase III Double-Blind Study of Dexamethasone Versus Placebo in the Prophylaxis of Radiation-Induced Pain Flare Following Palliative Radiotherapy for Bone Metastases Completed NCT01248585 Phase 3 Dexamethasone;Placebo
31 A Randomized, Double-Blind, Multicenter Study of Denosumab Compared With Zoledronic Acid in the Treatment of Bone Disease in Subjects With Newly Diagnosed Multiple Myeloma Completed NCT01345019 Phase 3 Denosumab;Zoledronic acid;Placebo to Denosumab;Placebo to zoledronic acid
32 Randomized Phase 2 Study on the Relationship Between Circulating VEGF and Weekly or Every-four-week Zometa in Breast Cancer Patients With Bone Metastases Completed NCT00524849 Phase 2, Phase 3 Zoledronic acid
33 Pain Education for Patients With Painful Bone Metastases Undergoing Palliative Radiotherapy: Reducing Pain by Increasing Patient's Knowledge and Self-management Completed NCT01358539 Phase 3
34 A Randomized, Phase III Study of Standard Dosing Versus Longer Dosing Interval of Zoledronic Acid in Metastatic Cancer Completed NCT00869206 Phase 3 zoledronic acid
35 Investigation of Optimal Radiotherapy Regimen and Type of Irradiation in Treatment of Painful Bone Metastasis Completed NCT00610272 Phase 3
36 Phase III Study of Palliative Radiotherapy for Bone Metastases Comparing Single to Multiple Fractions. Completed NCT00858741 Phase 3
37 Dexamethasone for the Prevention of a Pain Flare After Palliative Radiotherapy for Painful Bone Metastases: a Multi-center Double-blind Placebo-controlled Randomized Study Completed NCT01669499 Phase 3 Dexamethasone acetate;Placebo
38 Prophylactic Antibiotic Regimens in Tumor Surgery (PARITY): A Multi-Center International Randomized Controlled Trial Comparing Alternative Antibiotic Regimens in Patients Undergoing Tumor Resections With Endoprosthetic Replacements Recruiting NCT01479283 Phase 3 24-Hour Prophylactic Cefazolin* Antibiotic Regimen;5-Days Prophylactic Cefazolin* Antibiotic Regimen
39 Local Bisphosphonate Effect on Recurrence Rate in Extremity Giant Cell Tumor of Bone: A Prospective Randomized Controlled Trial Recruiting NCT03295981 Phase 3 Zoledronic Acid
40 Repeated Rhenium-188-HEDP Versus Radium-223-chloride in Patients With Metastatic Castration-resistant Prostate Cancer: The RaRe Study Recruiting NCT03458559 Phase 3 Radium-223 chloride;Rhenium-188-HEDP
41 Phase 3 Study Evaluating Fentanyl Transmucosal in the Prevention of Pain Induced by Mobilization During Radiotherapy in Patients With Bone Metastasis Recruiting NCT02426697 Phase 3 fentanyl transmucosal;Placebo
42 A Multi-Center Phase III, Randomized, Open-Label Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Combination With Irinotecan and Temozolomide as a Second-Line Regimen for Ewing's Sarcoma Recruiting NCT03495921 Phase 3 Irinotecan;Temozolomide
43 PD-Inhibitor (Nivolumab) and Ipilimumab Followed by Nivolumab vs. VEGF TKI Cabozantinib With Nivolumab: A Phase III Trial in Metastatic Untreated Renal Cell Cancer [PDIGREE] Recruiting NCT03793166 Phase 3 Cabozantinib
44 Prevention of Chemotherapy Induced Cardiotoxicity in Children With Bone Tumors and Acute Myeloid Leukemia Recruiting NCT03389724 Phase 3 Capoten®
45 A Randomized Trial Evaluating Rapid Delivery of Dose Escalated Hypofractionated Radiotherapy for Patients Diagnosed With Bone Metastases for Effective Palliation of Symptoms Active, not recruiting NCT02163226 Phase 3
46 Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma Active, not recruiting NCT02306161 Phase 3 Cyclophosphamide;Doxorubicin;Doxorubicin Hydrochloride;Etoposide;Etoposide Phosphate;Ifosfamide;Vincristine;Vincristine Sulfate
47 A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma Active, not recruiting NCT01231906 Phase 3 Cyclophosphamide;Doxorubicin Hydrochloride;Etoposide;Ifosfamide;Topotecan Hydrochloride;Vincristine Sulfate
48 Postoperative Bleeding Prevention in Massive Bone Tumour Resection: a Multicentric, Randomized, Parallel, Controlled Trial to Assess the Efficacy of Tranexamic Acid Versus Evicel® and Usual Haemostasis Terminated NCT02153593 Phase 3 Tranexamic Acid;Fibrin glue
49 A Randomized, Placebo-controlled, Double-blind Study of the Effect of Bondronat Compared With Zoledronic Acid on Pain in Patients With Malignant Bone Disease Experiencing Moderate to Severe Pain Terminated NCT00099203 Phase 3 ibandronate [Bondronat];zoledronic acid
50 A Cross-over Comparison of the Diagnostic Accuracy of Technetium (99mTc) Medronate Injection Prepared With 99mTc Derived From Neutron-activation Produced 99Mo Versus the Current Reference Standard of 99mTc Derived From Fission-produced 99Mo Terminated NCT03002454 Phase 3 99mTc MDP Injection:neutron-bombardment

Search NIH Clinical Center for Bone Cancer

Inferred drug relations via UMLS 72 / NDF-RT 51 :


ZOLEDRONIC
zoledronic acid

Cochrane evidence based reviews: bone neoplasms

Sources

Genetic Tests for Bone Cancer

About this section
Sources

Anatomical Context for Bone Cancer

About this section

MalaCards organs/tissues related to Bone Cancer:

41
Bone, Prostate, Breast, Lung, Spinal Cord, Dorsal Root Ganglion, Bone Marrow

The Foundational Model of Anatomy Ontology organs/tissues related to Bone Cancer:

19
Bone
Sources

Publications for Bone Cancer

About this section

Articles related to Bone Cancer:

(show top 50) (show all 1450)
# Title Authors PMID Year
1
Imaging of Upper Limb Tumors and Tumorlike Pathology. 17
31351534 2019
2
Beneficial effect of consolidative radiotherapy for patients with lymphoma and skeletal involvement. 17
31374054 2019
3
Endoscopic transnasal image-guided approach to diagnosis in orbital apex and optic canal lesions. 17
31271349 2019
4
Curcumin Releasing Eggshell Derived Carbonated Apatite Nanocarriers for Combined Anti-Cancer, Anti-Inflammatory and Bone Regenerative Therapy. 38
31039839 2019
5
Antibiotics drug release controlling and osteoblast adhesion from Titania nanotubes arrays using silk fibroin coating. 38
31349530 2019
6
Bioengineered silver nanoparticles capped with bovine serum albumin and its anticancer and apoptotic activity against breast, bone and intestinal colon cancer cell lines. 38
31146998 2019
7
Thalidomide alleviates bone cancer pain by down-regulating expressions of NF-κB and GFAP in spinal astrocytes in a mouse model. 38
30806135 2019
8
Dual-active targeting liposomes drug delivery system for bone metastatic breast cancer: Synthesis and biological evaluation. 38
31194968 2019
9
Anti-Tumor Effects of Low Dose Zoledronate on Lung Cancer-Induced Spine Metastasis. 38
31416169 2019
10
Combination of PARP inhibitor and temozolomide to suppress chordoma progression. 38
31201471 2019
11
In vitro and in vivo studies of antiosteosarcoma activities of formononetin. 38
30790283 2019
12
Identification of critical genes associated with human osteosarcoma metastasis based on integrated gene expression profiling. 38
31173206 2019
13
MiR-193a regulates chemoresistance of human osteosarcoma cells via repression of IRS2. 38
31193934 2019
14
Tissue-engineered 3D Models for Elucidating Primary and Metastatic Bone Cancer Progression. 38
31419564 2019
15
[EXPRESS] 2-Bromopalmitate attenuates bone cancer pain via reversing mitochondrial fusion and fission imbalance in spinal astrocytes. 38
31394961 2019
16
Exploring the Patients' Perception of Background and Breakthrough Pain: A McGill Pain Questionnaire Inquiry in Patients with Bone Cancer Pain. 38
31380726 2019
17
Cyclic nucleotide signaling in sensory neuron hyperexcitability and chronic pain after nerve injury. 38
31223142 2019
18
Exploration of quinolone and quinoline derivatives as potential anticancer agents. 38
31410781 2019
19
Spinal circRNA-9119 Suppresses Nociception by Mediating the miR-26a-TLR3 Axis in a Bone Cancer Pain Mouse Model. 38
31368062 2019
20
Identification and structure-activity relationship (SAR) of chemical constituents from Daemonorops draco (Willd.) Blume and selected commercial flavonoids on anti-osteoclastogenesis activity. 38
31376421 2019
21
SIRT1 Activation Attenuates Bone Cancer Pain by Inhibiting mGluR1/5. 38
31270711 2019
22
Imbalanced spinal infiltration of Th17/Treg cells contributes to bone cancer pain via promoting microglial activation. 38
30685532 2019
23
Targeting MOR-mGluR5 heteromers reduces bone cancer pain by activating MOR and inhibiting mGluR5. 38
31271770 2019
24
AAV-mediated siRNA against TRPV1 reduces nociception in a rat model of bone cancer pain. 38
31296147 2019
25
Downregulation of Cdc6 inhibits tumorigenesis of osteosarcoma in vivo and in vitro. 38
31100539 2019
26
Osteomimetic matrix components alter cell migration and drug response in a 3D tumour-engineered osteosarcoma model. 38
31302294 2019
27
Inhibition of protein kinase C activity inhibits osteosarcoma metastasis. 38
31360197 2019
28
EWSR1, a multifunctional protein, regulates cellular function and aging via genetic and epigenetic pathways. 38
30481590 2019
29
History of Dose, Risk, and Compensation Assessments for US Veterans of the 1966 Plutonium Cleanup in Palomares, Spain. 38
31283545 2019
30
High-resolution large-area imaging of nanoscale structure and mineralization of a sclerosing osteosarcoma in human bone. 38
31004766 2019
31
Personalized 3D-printed endoprostheses for limb sparing in dogs: Modeling and in vitro testing. 38
31327657 2019
32
Triple-threat activity of PEDF in bone tumors: Tumor inhibition, tissue preservation and cardioprotection against doxorubicin. 38
31028961 2019
33
High parental occupational social contact and risk of childhood hematopoietic, brain and bone cancers. 38
31369943 2019
34
Analgesia and curative effect of pamidronate disodium combined with chemotherapy on elderly patients with advanced metastatic bone cancer. 38
31289553 2019
35
Pharmacology of bisphosphonates in pain. 38
31347149 2019
36
XPro1595 ameliorates bone cancer pain in rats via inhibiting p38-mediated glial cell activation and neuroinflammation in the spinal dorsal horn. 38
31002915 2019
37
Nanoscale Hybrid Coating Enables Multifunctional Tissue Scaffold for Potential Multimodal Therapeutic Applications. 38
31260238 2019
38
Survival disparities for second primary malignancies diagnosed among childhood cancer survivors: A population-based assessment. 38
31251393 2019
39
Transcriptional Regulation of Voltage-Gated Sodium Channels Contributes to GM-CSF-Induced Pain. 38
31015342 2019
40
Paradoxical effects of JZL184, an inhibitor of monoacylglycerol lipase, on bone remodelling in healthy and cancer-bearing mice. 38
31151929 2019
41
Protein Kinase B and Extracellular Signal-Regulated Kinase Inactivation is Associated with Regorafenib-Induced Inhibition of Osteosarcoma Progression In Vitro and In Vivo. 38
31238539 2019
42
12b80 - Hydroxybisphosphonate Linked Doxorubicin: Bone Targeted Strategy for Treatment of Osteosarcoma. 38
31045351 2019
43
Mechanisms that drive bone pain across the lifespan. 38
30357885 2019
44
Identifying bone sarcoma survivors facing psychosocial challenges. A study of trajectories following treatment. 38
31184795 2019
45
Effects of Parecoxib on Pain Threshold and Inflammatory Factors IL-1β, IL-6 and TNF-𝜶 in Spinal Cord of Rats with Bone Cancer Pain. 38
31133150 2019
46
Kaempferol: A Key Emphasis to Its Anticancer Potential. 38
31248102 2019
47
The antinociceptive effect of resveratrol in bone cancer pain is inhibited by the Silent Information Regulator 1 inhibitor selisistat. 38
30592048 2019
48
Suppression of WNK1-SPAK/OSR1 Attenuates Bone Cancer Pain by Regulating NKCC1 and KCC2. 38
31085334 2019
49
[Study on analgesic effect and mechanism of cinobufagin on rats with bone cancer pain]. 38
31091577 2019
50
Interventional treatments for metastatic bone cancer pain. 38
31140913 2019
Sources

Variations for Bone Cancer

About this section

Copy number variations for Bone Cancer from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 70082 12 58138784 58142025 Amplification SAS Bone cancer
2 70083 12 58141509 58146230 Amplification CDK4 Bone cancer
3 71134 12 67700000 68661632 Amplification MDM2 Bone cancer
Sources

Expression for Bone Cancer

About this section
Search GEO for disease gene expression data for Bone Cancer.
Sources

Pathways for Bone Cancer

About this section

Pathways related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 17)
# Super pathways Score Top Affiliating Genes
1
TNFR1 Pathway 64
Show member pathways
 12.75 TNFSF11 TNFRSF11A MMP9 IL6 CYCS CCL2
2
Pathways in cancer 37
12.65 MMP9 IL6 ESR1 CYCS BMP2
3
Development Endothelin-1/EDNRA signaling 22
Show member pathways
 12.44 TRPV1 TNFSF11 TNFRSF11A CYCS COL1A1
4
Transcriptional misregulation in cancer 37
12 MMP9 IL6 EWSR1 BMI1
5
TNF signaling pathway 37
11.79 MMP9 IL6 CCL2
6
AGE-RAGE signaling pathway in diabetic complications 37
11.72 IL6 COL1A1 CCL2
7
Spinal Cord Injury 1
11.64 PDYN MMP9 IL6 CCL2
8
Microglia Activation During Neuroinflammation: Microglia Polarization 65
11.54 MMP9 IL6 CCL2
9
Senescence and Autophagy in Cancer 1
11.48 IL6 COL1A1 BMP2 BMI1
10
Lung fibrosis 1
11.45 MMP9 IL6 CCL2
11
Rheumatoid arthritis 37
11.23 TNFSF11 TNFRSF11A IL6 CCL2
12
Validated transcriptional targets of AP1 family members Fra1 and Fra2 1
11.03 MMP9 IL6 CCL2
13
G-protein signaling_RhoB regulation pathway 22
10.94 TNFSF11 IL6 CCL2 BMP2
14
Osteoclast Signaling 1
10.76 TNFSF11 TNFRSF11A
15
G-protein signaling_Rap2B regulation pathway 22
10.75 TNFSF11 PENK IL6 COL1A1 CCL2 BMP2
16
Osteoblast Signaling 1
10.68 TNFSF11 COL1A1
17
Transcription_Role of VDR in regulation of genes involved in osteoporosis 22
10.58 TNFSF11 TNFRSF11A IL6 COL1A1
Sources

GO Terms for Bone Cancer

About this section

Cellular components related to Bone Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.28 TNFSF11 RLN2 PENK PDYN MMP9 IL6

Biological processes related to Bone Cancer according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.96 TNFSF11 RLN2 P2RX7 IL6 BMP2
2 inflammatory response GO:0006954 9.95 TRPV1 P2RX7 IL6 CCL2 BMP2
3 cytokine-mediated signaling pathway GO:0019221 9.89 TNFSF11 MMP9 IL6 CCL2
4 response to lipopolysaccharide GO:0032496 9.84 TNFRSF11A PENK P2RX7 CNR1
5 positive regulation of NF-kappaB transcription factor activity GO:0051092 9.81 TRIM14 TNFSF11 TNFRSF11A IL6
6 positive regulation of apoptotic process GO:0043065 9.8 TRPV1 P2RX7 MMP9 IL6 CNR1 BMP2
7 response to bacterium GO:0009617 9.78 PENK P2RX7 CCL2 BMP2
8 response to estradiol GO:0032355 9.77 PENK ESR1 COL1A1
9 osteoblast differentiation GO:0001649 9.76 PENK MRC2 COL1A1 BMP2
10 cellular response to organic cyclic compound GO:0071407 9.74 P2RX7 CCL2 BMP2
11 positive regulation of ossification GO:0045778 9.58 P2RX7 BMP2
12 negative regulation of bone resorption GO:0045779 9.58 P2RX7 IL6
13 sensory perception of pain GO:0019233 9.56 TRPV1 PENK P2RX7 CNR1
14 mammary gland alveolus development GO:0060749 9.54 TNFSF11 TNFRSF11A ESR1
15 tooth eruption GO:0044691 9.52 TNFSF11 COL1A1
16 TNFSF11-mediated signaling pathway GO:0071847 9.49 TNFSF11 TNFRSF11A
17 monocyte chemotaxis GO:0002548 9.46 TNFSF11 TNFRSF11A IL6 CCL2
18 positive regulation of fever generation by positive regulation of prostaglandin secretion GO:0071812 9.43 TNFSF11 TNFRSF11A
19 positive regulation of ERK1 and ERK2 cascade via TNFSF11-mediated signaling GO:0071848 9.4 TNFSF11 TNFRSF11A
20 positive regulation of DNA-binding transcription factor activity GO:0051091 9.35 TRIM14 TNFSF11 TNFRSF11A IL6 ESR1
21 ossification GO:0001503 8.92 TNFSF11 TNFRSF11A COL1A1 BMP2

Molecular functions related to Bone Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytokine activity GO:0005125 9.26 TNFSF11 IL6 CCL2 BMP2
2 opioid peptide activity GO:0001515 8.62 PENK PDYN
Sources

Sources for Bone Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....